Hamid Taheri, MD
Cardiovascular Disease · Manassas, VANPI 1295773679
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $425,760 of the $501,449 with a category attached, or 84.9%. 59 manufacturers reported payments, led by Johnson & Johnson at 25.4% of the total. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,467 payments — averaging $341.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$128K
- Novo Nordisk$108K
- Amgen$74K
- Esperion Therapeutics, Inc.$71K
- Boehringer Ingelheim$53K
- Lilly USA, LLC$18K
- plus $50K from 53 others
Across 119 payments — averaging $36,587 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.9M
- Amgen$321K
- Eli Lilly$285K
- Merck$242K
- Astrazeneca UK Limited$222K
- Boehringer Ingelheim Pharma GmbH & Co.kg$88K
- plus $266K from 7 others
What the payments were for
- Consulting fees$16,4383%
- Speaking & faculty fees$425,76085%
- Travel & lodging$16,2173%
- Food & beverage$42,8229%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125,031
- NEXLETOL$69,083
- NEXLIZET$68,975
- JARDIANCE$68,732
- Repatha$64,141
- Wegovy$62,505
- FARXIGA$13,221
- Vascepa$7,873
- Impella$1,451
- Diamondback Coronary$1,441
- WATCHMAN Access System$1,002
- XACT$707
- Diamondback Peripheral$663
- Paradise Ultrasound Renal Denervation System$563
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$521
- FFRct$493
- Mitra Clip system$379
- CAMZYOS$366
- SYMPLICITY G3$326
- Barostim Neo System$289
How this compares
$501,449 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 164 | $227,904 |
| XareltoRivaroxaban | 156 | $191,782 |
| EntrestoSacubitril/Valsartan | 98 | $149,218 |
| JardianceEmpagliflozin | 103 | $123,796 |
| Repatha SureclickEvolocumab | 92 | $106,971 |
| OzempicSemaglutide | 74 | $69,496 |
| FarxigaDapagliflozin Propanediol | 39 | $48,174 |
| WegovySemaglutide | 29 | $41,610 |
| VascepaIcosapent Ethyl | 48 | $33,772 |
| NexlizetBempedoic Acid/Ezetimibe | 30 | $28,907 |
| BrilintaTicagrelor | 19 | $12,987 |
| Rosuvastatin Calcium | 572 | $12,441 |
| Metoprolol Succinate | 768 | $10,622 |
| Atorvastatin Calcium | 531 | $4,744 |
| Ezetimibe | 188 | $4,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $828 | $227,904164 claims |
| Johnson & JohnsonXarelto | $127,524 | $191,782156 claims |
| NovartisEntresto | $1,809 | $149,21898 claims |
| Boehringer IngelheimJardiance | $53,123 | $123,796103 claims |
| Novo NordiskOzempic, Wegovy | $108,085 | $111,106103 claims |
| AstraZenecaFarxiga, Brilinta | $14,578 | $61,16258 claims |
| Esperion Therapeutics, Inc.Nexlizet | $71,055 | $28,90730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Manassas
- Khalid AbousyManassas$68K
- Shahram YazdaniManassas$66K
- Balbir SidhuManassas$15K
- Shahryar MafiManassas$14K
- George VetrovecRichmond$2.3M
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.